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COST EFFECTIVENESS OF CEFTRIAXONE 
Marina Fenech 
Ceftriaxone is the first of the newer cephalosporins that can be 
administered safely and effectively in once-daily (or twice-daily) dosing 
schedule and that, in addition, possesses the broad spectrum of activity 
characteristic of the third generation cephalosporins. Given the 
pressures for cost containment that are now a major part of hospital life, 
drugs with favourable pharmacokinetic properties, should make it 
possible to realise considerable savings related to decreases in costs of 
administration. 
Methodology 
In an attempt to evaluate the cost-effectiveness of ceftriaxone, four 
studies were carried out: 
Study 1 
In this study, the daily dosage costs of ceftriaxone were compared with 
those of formulary and emergency I special requisition parenteral 
antibiotics currently used at St Luke's Hospitat G'Mangia. 
Study 2 
In the second study, the administration costs required for a four-daily 
dosage regimen, were compared to those required for a once-daily dosage 
regimen. Such costs per' pat~ent per day, included professional time 
necessary for drug administration and material costs. The total cost 
savings achieved through once-daily dosing regimen was applied to a 
minimum therapy duration of 1 week. 
Srudy3 
The net hospital costs for inpatient and outpatient (ceftriaxone) 
antimicrobial therapy were calculated, where the difference is 
equivalent to the potential cost savings possible through ceftriaxone 
outpatient therapy. The net hospital costs estimated included: 
The approximate cost of a training session. (On an outpatient basis, 
patients are trained to self-administer the medicament at home). 
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Cost of actual supplies used. 
An approximate evaluation of a follow-up visit. 
Bedding costs. 
Study 4 
This involved a clinical evaluation of ceftriaxone in surgical prophylaxis 
in gynaecological and obstetric surgery and urological surgery. The study 
thus consisted of two parts and involved a total of 70 patients. It was 
carried out over a period of 8 months (June 1991 - February 1992) and it 
was a random, single blind study. 
Results 
Study 1 
82.75% of the special requisition parenteral antibiotics are more 
expensive than ceftriaxone, on a daily dosage cost basis; these included 
also third generation cephalosporins like ceftazidime. On the other 
hand, only 25% of the formulary parenteral antibiotics have a more 
expensive daily dosage cost, when compared to ceftriaxone. These 
included cephalothin and cefotaxime (first and third generation 
respectively). 
Study 2 
Table 1. Comparison of administration costs 
Cost/week/patient 
includes professional 
time, syringes, etc. 
Once-daily 
Lm13.21 
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Four-daily Savings 
Lm59.92 Lm39.76 
Study 3 
Table 2. Potential cost-savings possible through outpatient therapy 
Inpatient 
cost 
Cost/ week/ patient 
includes bedding, 
tests, training, supplies Lm20.00 
Study 4 
Table 3. Perioperative surgical prophylaxis 
TAH 
Ceftriaxone group (n=25) 
Control group (n=25) 
PCNL 
Ceftriaxone group (n= 10) 
Control group (n= 10) 
Success 
75% 
80% 
Outpatient 
cost 
Lm21.00 
Failure 
12% 
4%* 
Success 
80% 
80% 
Savings 
Lm399.00 
Dubious 
Failure 
12% 
16% 
Failure 
20% 
20%** 
T AH: Total abdominal hysterectomy (obstetric and gynaecological 
surgery) 
PCNL: Percutaneous nephrolithotripsy (urological surgery) 
Control group in T AH surgical prophylaxis included a range of parenteral 
antimicrobials, given both in combination and as monotherapy, or 
no antibiotic therapy at all (3 cases) 
Control group in PCNL surgical prophylaxis included patients either on 
* 
** 
cefuroxime or norfloxacin or amoxycillin-clavulanate 
patient excluded from study because of concomitant diverticular 
disease dunng surgery; a strong predisposing factor to infection 
one patient is this category (=10%) excluded because of pre-
operative sepsis 
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Discussion 
All cephalosporins except cefuroxime, are more expensive than 
ceftriaxone on a daily dosage cost basis, when given in doses indicated for 
serious/life-threatening infections. Antimicrobial spectra for cefuroxime 
and ceftriaxone are also similar, and this explains why cefuroxime is a 
strong competing agent for ceftriaxone on the local market. 
As seen from Study 2, the administration costs saved through once-daily 
ceftriaxone therapy, are significant and may in fact balance out the extra 
costs incurred in those instances where ceftriaxone was found to have a 
superior daily dosage cost. 
Outpatient therapy with ceftriaxone is possible because of its favourable 
pharmacokinetics which afford a once daily dosing. Such outpatient 
programmes are not without limitations and patient compliance is 
perhaps the most important. Outpatient therapy again, compensates for 
cases shown in Study 1 where ceftriaxone was found to have a more 
expensive dosage. Therapeutic efficacy of ceftriaxone compares 
extremely well with that of othr antibiotics used as controls. 
Therapeutic success rates were similar or even identical in Study 4, 
although the incidence of dubious therapeutic failure and therapeutic 
failure cases did indicate a somewhat less superior nature of ceftriaxone -
as shown especially in the case of T AH surgical prophlaxis. However, it 
should be emphasised that the studY was characterised by a number of 
limitations which influenced the outcome, interpretation and credibility 
of such results, appreciably. 
Conclusions 
Ceftriaxone given on a once-daily basis is cost-effective and if used as a 
monotherapeutic agent this cost-effectiveness would be much augmented. 
However, the various cost benefits and other associated advantages 
achieved though mono therapy would prove futile and even life-
threatening if resistance were to emerge during therapy. Ceftriaxone 
monotherapy is thus indicated for non-nosocomial infections (mild-
moderate) and peri-operative surgical prophylaxis. Reinforcement of a 
clinical-pharmacist - infectious-disease physician team, instituted to 
review all cases of patients on antibiotic therapy may lead to a more 
regulated control of hospital expenses without meanwhile compromising 
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therapeutic efficacy. Certain antimicrobials may effectively be 
replaced by more cost-effective agents such as Ceftriaxone. 
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